Urological footprint of chronic kidney disease: A nephrologist perspective on early detection and collaborative management

Table 4 Clinical recommendations for bladder dysfunction in dialysis patients

Recommendation	Evidence grade	Practical notes/applicability
Use validated questionnaires (e.g., IPSS, OABSS) for early detection of LUTS in dialysis patients	2B	Low-cost, feasible in most clinical settings; useful for screening but limited by patient self-reporting bias
Perform uroflowmetry and PVR measurement in symptomatic patients	1B	Provides objective assessment; requires equipment and trained staff, may be less feasible in resource-limited centers
Refer dialysis patients with persistent LUTS to urology for further evaluation (urodynamics, cystoscopy if indicated)	1C	Strong recommendation despite limited trial data; referral may be challenging in rural/Low-resource areas
Implement bladder training and fluid management strategies to improve storage/voiding symptoms	2C	Non-invasive, low-cost, but requires patient adherence and education
Consider pharmacological therapy (e.g., antimuscarinics for BO, alpha-blockers for voiding dysfunction) when conservative measures fail	2B	Evidence mainly extrapolated from non-CKD populations; careful monitoring needed due to altered drug clearance in ESKD
Incorporate routine LUTS/QoL assessment into dialysis care protocols	1C	Improves holistic patient management; feasible with minimal resources if integrated into dialysis unit workflow

Where 1 = strong recommendation, 2 = weak; A = high-quality evidence, B = moderate, C = low. IPSS: International Prostate Symptom Score; OABSS: Overactive Bladder Symptom Score; LUTS: Lower urinary tract symptoms; BO: Bladder oversensitivity; QoL: Quality of life; CKD: Chronic kidney disease; ESKD: End-stage kidney disease.